Rhythm Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2018 Annual Meeting of Stockholders held by Rhythm Pharmaceuticals, Inc. on June 6, 2018. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Two Class I director nominees were elected to serve until the 2021 Annual Meeting.
- Keith M. Gottesdiener, M.D.: 20,795,988 votes For; 762,428 votes Withheld; 35,053 votes Abstaining; 1,697,431 Broker Non-Votes.
- Christophe R. Jean: 17,615,456 votes For; 3,942,960 votes Withheld; 35,053 votes Abstaining; 1,697,431 Broker Non-Votes.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified.
- Votes For: 23,246,337
- Votes Against: 8,558
- Votes Abstaining: 36,005
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Christophe R. Jean received a significantly higher number of withheld votes (3,942,960) compared to Keith M. Gottesdiener (762,428), representing approximately 18% of the votes cast for that nominee versus approximately 3.5% for the other.
- Ernst & Young LLP was overwhelmingly ratified as the independent auditor with over 99% of votes cast in favor.
- Broker non-votes totaled 1,697,431 for the director elections, which may impact the total voting power available for future proposals.